ACADIA PHARMACEUTICALS INC 8-K

What Happened
Acadia Pharmaceuticals Inc. filed a Form 8-K reporting that Elizabeth H.Z. Thompson, Ph.D., the Company’s Head of Research and Development, informed the company on April 27, 2026 that she plans to retire for personal reasons. The company issued a press release on April 30, 2026 announcing the planned retirement. Dr. Thompson will remain in her Head of R&D role during a transitional period until a successor is appointed and has agreed to serve as a consultant through the end of 2026, including through the planned readout of the Company’s Phase 2 clinical study of remlifanserin in Alzheimer’s disease psychosis.

Key Details

• Notification date: April 27, 2026; press release issued April 30, 2026.
• Executive: Elizabeth H.Z. Thompson, Ph.D., Head of Research & Development.
• Transition plan: Continue in current role until a successor is named; then act as consultant through Dec 31, 2026 (including the planned Phase 2 readout).
• Company action: Search for a replacement has been initiated.

Why It Matters
This is a material leadership change in Acadia’s R&D organization during an important clinical milestone—the planned Phase 2 readout for remlifanserin in Alzheimer’s disease psychosis later in 2026. Investors tracking Acadia’s pipeline should note the planned continuity (Dr. Thompson staying through the readout as employee then consultant) and that the company has begun a formal search for a successor. The filing does not disclose timing for appointing a new Head of R&D or any changes to development timelines.